Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
9.41 CHF
977.57 M CHF
7.93 B CHF
144.59 M
About Biogen Inc.
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
FIGI
BBG006TLND59
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where BIIB is featured.
Frequently Asked Questions
The current price of BIIB is 232.00 CHF — it hasn't changed in the past 24 hours. Watch BIOGEN IDEC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange BIOGEN IDEC stocks are traded under the ticker BIIB.
We've gathered analysts' opinions on BIOGEN IDEC future price: according to them, BIIB price has a max estimate of 297.55 CHF and a min estimate of 156.60 CHF. Watch BIIB chart and read a more detailed BIOGEN IDEC stock forecast: see what analysts think of BIOGEN IDEC and suggest that you do with its stocks.
BIIB reached its all-time high on Mar 24, 2015 with the price of 426.68 CHF, and its all-time low was 207.63 CHF and was reached on Jun 22, 2016. View more price dynamics on BIIB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BIIB stock is 0.00% volatile and has beta coefficient of 0.68. Track BIOGEN IDEC stock price on the chart and check out the list of the most volatile stocks — is BIOGEN IDEC there?
Today BIOGEN IDEC has the market capitalization of 21.73 B, it has decreased by −0.09% over the last week.
Yes, you can track BIOGEN IDEC financials in yearly and quarterly reports right on TradingView.
BIOGEN IDEC is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
BIIB earnings for the last quarter are 3.46 CHF per share, whereas the estimation was 3.20 CHF resulting in a 8.15% surprise. The estimated earnings for the next quarter are 3.05 CHF per share. See more details about BIOGEN IDEC earnings.
BIOGEN IDEC revenue for the last quarter amounts to 2.09 B CHF, despite the estimated figure of 2.06 B CHF. In the next quarter, revenue is expected to reach 2.14 B CHF.
BIIB net income for the last quarter is 329.23 M CHF, while the quarter before that showed 524.68 M CHF of net income which accounts for −37.25% change. Track more BIOGEN IDEC financial stats to get the full picture.
No, BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN IDEC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN IDEC EBITDA is 2.33 B CHF, and current EBITDA margin is 22.58%. See more stats in BIOGEN IDEC financial statements.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN IDEC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN IDEC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN IDEC stock shows the sell signal. See more of BIOGEN IDEC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.